Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.30.1 (
S1 nuclease
)
3,660
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Most approaches to studying messenger RNA (mRNA) decay in vivo lack sufficient sensitivity to identify decay intermediates. The identification of such intermediates using in vitro decay systems can provide suggestive evidence for endonuclease-mediated degradation in vivo; to validate conclusions drawn from in vitro experiments one must demonstrate cleavage of the mRNA in vivo. Primer extension or
S1 nuclease
protection assays work best on relatively abundant mRNAs and even then require long exposure times. We describe a facile approach using ligation-mediated polymerase chain reaction to identify in vivo mRNA decay intermediates. In this procedure, total cellular RNA is ligated to a primer bearing a 5' phosphate and 3' amino group. Reverse transcription is primed using a complementary primer, and mRNA-specific decay intermediates are identified by polymerase chain reaction amplification using a 5'- [32P]-labeled gene-specific primer. Products generated in this manner are gel purified, reamplified, and the 3' end of each decay intermediate is identified by the sequence junction of the specific mRNA and the initial ligation primer. We show an example of the time-course of appearance of several specific decay intermediates of
c-myc mRNA
in differentiating murine erythroleukemia cells.
...
PMID:Application of ligation-mediated reverse transcription polymerase chain reaction to the identification of in vivo endonuclease-generated messenger RNA decay intermediates. 1477 8
<< Previous
1
2